GlaxoSmithKline (GSK) Announces Earnings Results, Beats Estimates By $0.03 EPS

GlaxoSmithKline (NYSE:GSK) announced its earnings results on Wednesday. The pharmaceutical company reported $0.72 EPS for the quarter, topping the Zacks’ consensus estimate of $0.69 by $0.03, Morningstar.com reports. GlaxoSmithKline had a return on equity of 115.30% and a net margin of 7.79%. The company had revenue of $10.14 billion for the quarter, compared to analysts’ expectations of $9.89 billion.

GlaxoSmithKline (GSK) traded up $0.92 during trading hours on Thursday, reaching $36.95. The company’s stock had a trading volume of 2,023,564 shares, compared to its average volume of 5,173,329. The company has a current ratio of 0.64, a quick ratio of 0.44 and a debt-to-equity ratio of 2.96. The company has a market capitalization of $91,350.00, a PE ratio of 42.94, a PEG ratio of 2.31 and a beta of 0.98. GlaxoSmithKline has a twelve month low of $34.52 and a twelve month high of $44.53.

A number of equities analysts recently commented on GSK shares. JPMorgan Chase & Co. reaffirmed a “neutral” rating on shares of GlaxoSmithKline in a report on Wednesday, October 18th. Zacks Investment Research raised GlaxoSmithKline from a “hold” rating to a “buy” rating and set a $46.00 target price on the stock in a report on Wednesday, October 18th. Bank of America cut GlaxoSmithKline from a “buy” rating to a “neutral” rating in a report on Thursday, October 26th. TheStreet raised GlaxoSmithKline from a “c+” rating to a “b” rating in a report on Wednesday, October 25th. Finally, Investec cut GlaxoSmithKline from a “buy” rating to a “hold” rating in a report on Monday, November 6th. Three equities research analysts have rated the stock with a sell rating, ten have given a hold rating and six have assigned a buy rating to the company. The stock has a consensus rating of “Hold” and an average price target of $38.57.

Large investors have recently bought and sold shares of the business. Wealthcare Advisory Partners LLC raised its holdings in GlaxoSmithKline by 1,982.8% during the third quarter. Wealthcare Advisory Partners LLC now owns 3,520 shares of the pharmaceutical company’s stock valued at $143,000 after acquiring an additional 3,351 shares during the period. Field & Main Bank bought a new stake in GlaxoSmithKline during the fourth quarter valued at about $132,000. First Dallas Securities Inc. bought a new stake in shares of GlaxoSmithKline in the fourth quarter worth about $142,000. Advisory Services Network LLC increased its holdings in shares of GlaxoSmithKline by 24.2% in the second quarter. Advisory Services Network LLC now owns 4,047 shares of the pharmaceutical company’s stock worth $175,000 after purchasing an additional 788 shares during the last quarter. Finally, Quadrant Capital Group LLC increased its holdings in shares of GlaxoSmithKline by 3.5% in the second quarter. Quadrant Capital Group LLC now owns 4,345 shares of the pharmaceutical company’s stock worth $162,000 after purchasing an additional 148 shares during the last quarter. 9.66% of the stock is currently owned by institutional investors and hedge funds.

ILLEGAL ACTIVITY WARNING: “GlaxoSmithKline (GSK) Announces Earnings Results, Beats Estimates By $0.03 EPS” was originally posted by American Banking News and is the property of of American Banking News. If you are reading this report on another site, it was stolen and republished in violation of United States & international copyright legislation. The legal version of this report can be viewed at https://www.americanbankingnews.com/2018/02/08/glaxosmithkline-gsk-announces-earnings-results-beats-estimates-by-0-03-eps.html.

GlaxoSmithKline Company Profile

GlaxoSmithKline plc is a global healthcare company. The Company operates through three segments: Pharmaceuticals, Vaccines and Consumer Healthcare. The Company focuses on its research across six areas: Respiratory diseases, human immunodeficiency virus (HIV)/infectious diseases, Vaccines, Immuno-inflammation, Oncology and Rare diseases.

Earnings History for GlaxoSmithKline (NYSE:GSK)

Receive News & Ratings for GlaxoSmithKline Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for GlaxoSmithKline and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply